Adagene Inc. (ADAG)
Upgrades & Downgrades
Latest ADAG news
Are Medical Stocks Lagging Adagene (ADAG) This Year?
7 September 2023
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
Adagene to Present at Investor and Scientific Conferences in September
7 September 2023
– Adagene's CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
25 May 2023
Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
5 January 2023
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
Adagene to Participate in Investor Conferences in May and June
12 May 2022
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ann...
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
17 March 2022
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumo...
16 March 2022
The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizuma...
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
10 March 2022
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio...
Sanofi to pay up to $2.5 billion in deal with Adagene
2 March 2022
Shares of Adagene Inc. ADAG, +1.10% jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi SNY, -2.65% that is worth up to $2.5 billion. U...
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
8 February 2022
SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...